Abstract. Metastatic circulating tumor cells in non-small cell lung cancer (NSCLC) metastasis have been reported to be associated with an immune response. The present study aimed to provide a theoretical basis for the immunomodulatory processes during NSCLC blood metastasis. NSCLC blood and normal peripheral blood mononuclear cells (PBMCs) were collected. The quantity of cluster of differentiation (CD)4 + CD25 high regulatory T (Treg) cells and the intracellular forkhead box protein 3 (Foxp3) expression in CD4 + CD25 high Treg cells were determined by flow cytometry. Furthermore, the effect of transforming growth factor β1 (TGF-β1) on NSCLC blood CD4 + CD25 + Treg cell proliferation was explored by activating blood mononuclear cells with an anti-CD3 monoclonal antibody, interleukin-2 and different doses of TGF-β1. Reverse transcription-quantitative polymerase chain reaction assays were used to detect the mRNA expression of Foxp3. Carboxyfluorescein succinimidyl ester staining was used to analyze the proliferation dynamics of lymphocyte subsets. Results indicate that the proportion of CD4 + T cells in the blood of patients with NSCLC was significantly higher compared with normal peripheral blood (P<0.01). 
Introduction
A special class of regulatory T (Treg) cells, cluster of differentiation (CD)4 + CD25 + Treg cells, characterized by high expression of interleukin-2 (IL-2) receptor α-chain, exists in the peripheral blood and spleen of normal humans and mice (1, 2) . Treg cells are divided into two categories: Natural regulatory T cells (nTreg), which are produced in the thymus (3) and induced Treg cells (iTreg), which are induced by inhibitive cytokines, drugs and immature dendritic cells in vitro or in vivo (4, 5) . Recently, studies have demonstrated that CD4 + CD25 + Treg cells with low reactivity and immunosuppressive properties may serve an important role in maintaining homeostasis within the internal environment, and inducing transplantation tolerance, autoimmune diseases, the response to infections and tumor immunity (6) (7) (8) . The proportion of Treg cells in normal peripheral blood, which has immunosuppressive or tumor immunity abilities, is very small, accounting for 1-3% of peripheral blood CD4 + T cells (9, 10) . Forkhead box protein 3 (Foxp3) belongs to the forkhead/winged-helix transcription factor family and displays a fork-like helical, a C2H2 zinc finger and a leucine zipper structure (11, 12) . In humans, Foxp3 is located at p11.23-q13.3 on the X chromosome, containing 11 exons and 10 introns. It encodes a 48 kDa protein, Scurfin, which is a key factor in Treg cell development and immunosuppressive function (13, 14) . Jiang et al (15) reported that Foxp3 protein was more specific than CD4, CD25 and other surface markers, serving a pivotal role in the inhibitive function of Treg cells. -β1 on blood CD4   +   CD25   high   regulatory  T cell proliferation and Foxp3 expression during non-small cell lung cancer blood metastasis Schoenbrunn et al (16) (17) reported that Foxp3 expression determined the regulatory ability of Treg cells and Foxp3 overexpression could lead to a low immune activity status in the body, which illustrated that Foxp3 was the central regulator of Treg cell activity.
Effect of TGF
Circulating tumor cells (CTCs) are a type of tumor cell that enters the peripheral blood circulation from the primary tumor or metastasis (18) . Over the course of a malignancy, tumors may spread from the local site to the blood or lymph circulation. The clinical relevance of CTCs and metastasis has been confirmed in metastatic breast cancer, colorectal cancer and prostate cancer (19) . There are numerous reports on the correlation between non-small-cell lung cancer (NSCLC) metastasis and CTCs (18, 20) . Additionally, the CTCs in NSCLC metastasis were reported to cause immune responses, including both proinflammatory and anti-inflammatory regulation (21, 22 To analyze the differences between NSCLC and normal peripheral blood, the immune suppressive ability of CD4 + CD25 + Treg cells, the number of CD4 + CD25 high Treg cells and Foxp3 expression were measured. In addition, due to low immunogenicity and strong regeneration ability, TGF-β1 was used to produce iTreg cells with tumor inhibitive functions in the process of NSCLC blood mononuclear cell (BMC) culturing. Furthermore, protein and mRNA expression of Foxp3 were monitored by flow cytometry and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay. To explore the role of TGF-β1 in NSCLC blood iTreg cells, proliferative response of iTreg cells induced by TGF-β1 was analyzed by carboxyfluorescein succinimidyl ester (CFSE) staining. The present study aimed to provide a potential new route for clinical immunotherapy during NSCLC blood metastasis.
Materials and methods
The present study was approved by the Medical Ethics Committee of Jiaxing No.1 Hospital (approval no. JY201513R; Jiaxing, China). A total of 231 patients (age, 67±15 years old; 65% male) who underwent clinical treatment in Jiaxing No. 1
Hospital were enrolled from January 2016 to December 2017. All patients provided written informed consent. The procedure of the study strictly followed the Declaration of Helsinki. Blood samples were collected according to normal clinical practice.
Preparation of NSCLC BMCs and normal peripheral
BMCs (PBMCs). NSCLC and normal peripheral blood were collected, restored in heparin anticoagulation (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) and diluted with an equal amount of Roswell Park Memorial Institute (RPMI)-1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA). The blood was treated with lymphocyte separation liquid (Beyotime Institute of Biotechnology, Haimen, China). Mononuclear cells were isolated by density gradient centrifugation (400 x g, 20 min, 20˚C), washed twice with serum-free RPMI-1640 (400 x g, 10 min, 4˚C, followed by 300 x g, 10 min, 4˚C) and adjusted to 1-2x10 6 cells/ml with RPMI l640 containing 10% human autologous serum (Gibco; Thermo Fisher Scientific, Inc.) and 50 ml/l N-bromosuccinimide (NBS; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).
NSCLC BMC labeling by CFSE. Cells were analyzed using a flow cytometer. Briefly, CFSE (Molecular Probes; Thermo Fisher Scientific, Inc.) was dissolved in dimethyl sulfoxide (2 mmol/l) and stored at -80˚C following aliquoting. Serum-free RPMI-1640 was used to adjust BMCs to 1x10 7 cells/ml. Fluorescence intensity of the parent generation cells labeled by CFSE (FL1) at 10 4 -10 6 cells per 200 µl well was determined in a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). CFSE stock solution was added to the cell suspension to achieve a final concentration of 1.6 µmol/l. Following staining at 37˚C for 10 min, the cells were washed three times with RPMI-1640 containing 10% human autologous serum and 100 ml/l NBS to remove excess dye and adjusted to 1x10 6 cells/ml with RPMI 1640 containing 10% human autologous serum and 50 ml/l NBS. The cells were assessed using a flow cytometer and evaluated through an auto-analyze method using ModFit software (version 4.1; Verity Software House, Topsham, ME, USA).
T cell culturing and proliferation. A total of 10 4 -10 6 BMCs were added to 24-well cell culture plates at 1 ml per well and incubated with anti-CD3 monoclonal antibodies (3 µg/ml; cat. no. ab11089; Abcam, Cambridge, MA, USA) and IL-2 (100 U/ml; PeproTech, Inc., Rocky Hill, NJ, USA). Experimental groups were defined by the addition of varying concentrations (1, 5 and 25 ng/ml) of recombinant human TGF-β1 (PeproTech, Inc.). Cells were cultured at 37˚C, 5% CO 2 and harvested on day 4. Experiments were performed in triplicate.
Proliferation of T cell subsets analyzed by flow cytometry.
Flow cytometry was performed according to a previous study (19) . T cell subsets were collected. The following antibodies were applied to stain for CD3, CD4, CD8 on the cell surface with different colored fluorophores, following previous reports (23): Anti-CD3-PE/Cy5.5 ® (cat. no. ab190285) and anti-CD8-PE/Cy7 ® (cat. no. ab39853) or anti-CD3-APC (1:5,000; cat. no. 17-0036-42; Invitrogen; Thermo Fisher Scientific, Inc), anti-CD4-PerCP/Cy5.5 (cat. no. ab210324) and anti-CD25-PE/Cy7 (cat. no. ab210335; all 1:5,000; Abcam). Proliferation of T cell subsets was analyzed by flow cytometry. CFSE was considered as the first fluorescence (FL1), PE-labeled antibody as the second fluorescence (FL2), PeCy5.5 as the third fluorescence (FL3), APC as the fourth fluorescence (FL4). Flow cytometry was assessed using FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA). Cell Quest software (version 5.1; BD Biosciences) was used for analyzing the data. The cell proliferation ability and the proportions of CD4 + CD25 + and CD8 + T cells were calculated with the Cell Quest software.
Analysis of Foxp3 expression in CD4
+ CD25 + Treg cells by flow cytometry. Following the collection of 3x10 5 BMCs and PBMCs cultured at different TGF-β1 concentration (~300 µl/tube), cells were washed with eBioscience™ Flow Cytometry Staining Buffer (Invitrogen; Thermo Fisher Scientific, Inc.) and centrifuged at 300 x g for 5 min at 4˚C. The supernatant was discarded; cells were re-suspended in PBS and incubated with anti-human CD3-APC, anti-human CD25-PE/Cy7 and anti-human CD4-PerCP/Cy5.5 antibodies for cell surface staining at 4˚C for 30 min. Cells were then washed twice with staining buffer, re-suspended, centrifuged at 300 x g for 5 min at 4˚C and fixed with paraformaldehyde (PFA; cat. no. A500684; 20 g/l; ~500 µl/tube; Sangon Biotech Co., Ltd., Shanghai, China) at 4˚C for 30 min. The supernatant was discarded after centrifugation (300 x g for 5 min at 4˚C) and the cells were washed twice with staining buffer. The cells were incubated with a permeable membrane buffer, Fixation/Permeabilization Solution kit with BD GolgiStop™ (BD Biosciences) at 4˚C for 15 min. Cells were centrifuged at 400 x g for 15 min at 4˚C and the supernatant was discarded. Staining was performed with anti-human Foxp3-fluorescein isothiocyanate (FITC; 5 µl (0.5 µg)/test; cat. no. 11-4776-41; Invitrogen; Thermo Fisher Scientific, Inc.) at 4˚C for 30 min. Cells were washed with permeable membrane buffer and with staining buffer. PFA (10 g/l; ~300 µl/tube) was added and Foxp3 expression in CD4 + CD25 + Treg cells was analyzed by flow cytometry. The control group was prepared without intracellular Foxp3 stain and mouse Immunoglobulin G1-FITC (5 µl (0.5 µg)/test; cat. no. 11-4015-80; Invitrogen; Thermo Fisher Scientific, Inc.) intracellular staining was used as isotype control. Anti-CD3-FITC (cat. no. ab34275; Abcam), anti-CD4-PE (cat. no. ab134354; Abcam), anti-CD3-PE/Cy5.5 or anti-CD3-APC antibodies were used for quality control of the flow cytometer prior to the experiments, as recommended by a previous report (23) .
mRNA expression of Foxp3 is detected by RT-qPCR. Total RNA from NSCLC BMCs and normal peripheral BMCs was isolated using TRIzol ® reagent (Invitrogen) according to the manufacturer's protocol. NanoDrop-1000 (Thermo Fisher Scientific, Inc.) was used to determine the concentration and purity of total RNA. A GoScript™ reverse transcription kit (Promega, Madison, WI, USA) was used to synthesize the first strand of cDNA with 1 µg total RNA. RT-qPCR assay was used to detect the mRNA expression of transcription factor Foxp3 (forward primer: 5'-CTG GCG AAG GGC TCG GTA GTC CT-3', reverse primer: 5'-CTC CCA GAG CCC ATG GCA GAA GT-3') using a PowerUp™ SYBR ® Green kit (cat. no. A25778; Thermo Fisher Scientific, Inc). GAPDH (cat. no. B661104-0001; Sangon Biotech Co., Ltd.) mRNA served as a loading controls (forward primer: 5'-AAT GCA TCC TGC ACC ACC AA-3' and reverse primer: 5'-GTA GCC ATA TTC ATT GTC ATA-3'). The thermocycling protocol was performed as previously described (25 Fig. 2A and B) . For CD8 + T cells, G0-4 accounted for 94.18% (treated) and 95.62% (untreated), and the G5-6 accounted for 5.70% (treated) and 4.83% (untreated) on day 4 of all CD8 + T cells at that time point ( Fig. 2A and B) . On day 6, the amount of CD4 + CD25 + Treg cells from G0-4 was 18.65% (treated) and 45.01% (untreated) of all CD4 + CD25 + Treg cells at that time point, and for G5-8, the proportion of CD4 + CD25 + Treg cells was determined to be 81.29% (treated) and 55.20% (untreated) (Fig. 2C and D) . For CD8 + T cells on day 6, the proportion from G0-4 were 55.92% (treated) and 77.73% (untreated), while the proportion for G5-8 were 44.04% (treated) and 23.20% (untreated), respectively ( Fig. 2C and D) . On day 8, CD4 + CD25 + Treg cells for G0-4 accounted for 8.54% (treated) and 9.54% (untreated), and for G8-10 accounted for 54.35% (treated) and 34.79% (untreated) of all CD4 + CD25 + Treg cells at that time point (Fig. 2E and F) . For CD8 + T cells, the proportion for G0-4 was 42.43% (treated) and 66.20% (untreated), while the proportion for G8-10 and 13.86% (treated) and 7.46% (untreated) were determined, respectively (Fig. 2E and F) . Blue and orange arrows reveal increased proliferation (or proliferation trend) of CD4 + CD25 + Treg and CD8 + T cells. The arrows shift from the prior generations to later generations in Fig. 2A , C and E. In addition, proportions of CD4 + CD25 + Treg and CD8 + T cells were significantly increased following treatment with TGF-β1 on G6-8 at day 6 and G8-9 at day 8 ( Fig. 2C and E) compared with untreated cells ( Fig. 2D and F (Fig. 4A) . However, the proportion of CD4 + CD25 high Foxp3 + T cells was significantly increased in the treatment groups compared with control group (all P<0.05; Fig. 4A and B) . Foxp3 expression in CD4 + CD25 high T cells treated with 1, 5 and 25 ng/ml TGF-β1 was 69.24±4.91%, 81.99±5.29% and 72.34±3.41%, respectively; it was significantly increased compared with the control group (42.38±2.13%; P<0.05; Fig. 4C and D) . It was demonstrated that CD4 + CD25 -T cells displayed negligible Foxp3 expression (data not shown).
Discussion

CD4
+ CD25 + Treg cells are a subset of T cells serving a central role in maintaining the body's peripheral immune tolerance, including tumor surveillance progress (6) (7) (8) . Previous reports have demonstrated that abnormal numbers of CD4 + CD25 + Treg cells or CD4 + CD25 + Treg cell dysfunction are closely associated with autoimmune diseases, cancer, infectious diseases, organ transplant rejection, allergic diseases and other diseases (25, 26) . CD4 + CD25 + Treg cells overexpress the IL-2 receptor α chain, the cytotoxic T lymphocyte associated antigen-4, the IL-2 receptor β chain, neuropilin-1, the glucocorticoid-induced tumor necrosis factor receptor, integrin αE, the chemokine receptor (CCR)4 and CCR8 (27, 28) . However, these molecules are all expressed on activated CD4 + effector T cells, with a lack of specificity. In addition to these molecules, Guo et al (29) (38) reviewed studies of TGF-β1 induced Foxp3 + Treg cells in both mouse and human. However, the molecular mechanism underlying the upregulation of Foxp3 expression induced by TGF-β1 in CD4 + CD25 + T cells requires further exploration.
Immune regulation in tumor metastasis demands a complex balance (39) . Enhancing or suppressing immunity may cause totally different effects. This preliminary study indicates that NSCLC blood CD4 + CD25 high Treg cells may be functionally immature. The induction of the immune naive precursor cells in NSCLC blood by Treg cells with strong immunosuppressive ability may provide a new basis for the prognosis and treatment of NSCLC blood metastasis in the future.
